Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer's and Parkinson's diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The engagements offer the company opportunities to detail its clinical progress and upcoming milestones to biotechnology and pharmaceutical industry representatives.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled "Bridging the Translational Gap: From Discovery Insights to Clinical Proof" on Nov. 16 from 9:15-9:45 a.m. ET. She will also deliver a company presentation from 10:15-10:30 a.m. ET highlighting Annovis' clinical programs and upcoming milestones. The panel and presentation place the company's lead candidate before an audience focused on moving discoveries from the laboratory into clinical validation.
Maccecchini will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled "Restoring Proteostasis in Alzheimer's and Parkinson's Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins," will take place Nov. 19 from 11:25-11:55 a.m. ET. During both events, she will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company's clinical progress and potential opportunities.
Headquartered in Malvern, Pennsylvania, Annovis Bio is developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The conference appearances matter because they give Annovis a platform to explain how buntanetap's mechanism differs from approaches that target a single protein. Alzheimer's and Parkinson's are progressive disorders with substantial unmet need, and a therapy that simultaneously reduces several neurotoxic proteins could represent a meaningful advance if clinical trials confirm the approach. The one-on-one meetings may also open doors to potential partnerships or other strategic opportunities.
For investors, the presentations could provide visibility into the company's clinical timelines and upcoming milestones, which are closely watched for a Phase 3-stage biotech. For the broader industry, the events underscore the continuing focus on translational research and proteostasis as a therapeutic strategy in neurodegeneration. More information about the company is available through its www.annovisbio.com, and the full press release is available at https://ibn.fm/0D5yA. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. Annovis Bio's relationship with Annovis Bio (NYSE: ANVS) is covered through MissionIR, a communications platform within the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and social media distribution, among other corporate communications solutions.
